BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 2422129)

  • 41. Inhibition of experimentally-induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases.
    Brunda MJ; Rosenbaum D; Stern L
    Int J Cancer; 1984 Sep; 34(3):421-6. PubMed ID: 6480158
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of recombinant murine interferon-gamma and human interferon-alpha A/D(Bgl) administered in concert and their influence on natural killer cell function in mice.
    Chen SA; Shalaby MR; Crase DR; Palladino MA; Baughman RA
    J Interferon Res; 1988 Oct; 8(5):597-608. PubMed ID: 3148670
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.
    Itoh K; Pellis NR; Balch CM
    Cancer Immunol Immunother; 1989; 29(1):57-62. PubMed ID: 2785000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective impairment of alpha-interferon-mediated natural killer augmentation in Sjögren's syndrome: differential effects of alpha-interferon, gamma-interferon, and interleukin 2 on cytolytic activity.
    Takeda A; Minato N; Kano S
    Clin Exp Immunol; 1987 Nov; 70(2):354-63. PubMed ID: 2448073
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.
    Chao TY; Ohnishi H; Chu TM
    Mol Biother; 1989; 1(6):318-22. PubMed ID: 2610950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulation of human natural killer cell activity by interferon-gamma: lack of a role in interleukin 2-mediated augmentation.
    Sayers TJ; Mason AT; Ortaldo JR
    J Immunol; 1986 Mar; 136(6):2176-80. PubMed ID: 3081640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro.
    McVicar DW; Merchant RE; Merchant LH; Young HF
    Cancer Immunol Immunother; 1989; 29(3):211-8. PubMed ID: 2499421
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro combined effects of human interferons and interleukin-2 on natural cell-mediated cytotoxicity.
    Fuggetta MP; Aquino A; Pepponi R; D'Atri S; Lanzilli G; Bonmassar E; Graziani G
    Int J Immunopharmacol; 1993 Jan; 15(1):1-10. PubMed ID: 7679378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The role of interferons in neuroblastoma. 2: Immunomodulatory effects].
    Handgretinger R; Bruchelt G; Daurer B; Lang P; Dopfer R; Reisfeld RA; Treuner J; Niethammer D
    Klin Padiatr; 1990; 202(4):206-11. PubMed ID: 2118581
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acidic polysaccharide from Panax ginseng, ginsan, induces Th1 cell and macrophage cytokines and generates LAK cells in synergy with rIL-2.
    Kim KH; Lee YS; Jung IS; Park SY; Chung HY; Lee IR; Yun YS
    Planta Med; 1998 Mar; 64(2):110-5. PubMed ID: 9525101
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fucose-activated killer (FAK) cells: anomalous killers with augmented cytotoxic activity.
    Stanková J; Rola-Pleszczynski M
    J Immunol; 1985 Dec; 135(6):3719-28. PubMed ID: 2415584
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells.
    Jewett A; Bonavida B
    J Clin Immunol; 1995 Jan; 15(1):35-44. PubMed ID: 7759599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
    J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generation of lymphokine-activated killer cell activity from human thymocytes.
    Ramsdell FJ; Golub SH
    J Immunol; 1987 Sep; 139(5):1446-53. PubMed ID: 2442246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alteration of human lymphokine-activated killer cell activity by manipulation of protein kinase C and cytosolic Ca2+.
    McCrady CW; Li F; Grant AJ; Merchant RE; Carchman RA
    Cancer Res; 1988 Feb; 48(3):635-40. PubMed ID: 3257170
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential antiproliferative effects of combinations of recombinant interferons alpha and gamma on two murine tumor cell lines.
    Brunda MJ; Wright RB
    Int J Cancer; 1986 Feb; 37(2):287-91. PubMed ID: 3080378
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of lymphokine-activated killer and natural killer cell activities from cryopreserved lymphocytes.
    Kawai H; Komiyama A; Katoh M; Yabuhara A; Miyagawa Y; Akabane T
    Transfusion; 1988; 28(6):531-5. PubMed ID: 3264091
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of interleukin-2 and interferon-gamma in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.
    Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K; Kuribayashi K; Saito K
    Cancer Immunol Immunother; 1989; 29(2):79-86. PubMed ID: 2497980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.